Literature DB >> 30369747

Effect of FFP Transfusion on International Normalized Ratio in Liver Disease Patients.

Sukanya Baruah1, Meenu Bajpai1.   

Abstract

Fresh frozen plasma (FFP) is widely used in liver diseases to rectify coagulation derangements. In this study we have analysed the pattern of FFP usage in liver diseases and its effect on International normalized ratio (INR). A retrospective study of liver disease patients who received FFP transfusions from January 2016 to June 2016 was done. FFP used for liver transplant surgeries and plasma exchange procedures were excluded from the study. A total of 1935 units of FFP were transfused to 576 patients. We found a high linear correlation between pre transfusion INR and change in INR per unit of FFP. Patients receiving 6 units or more FFP have shown significant INR improvement. Improvement was more in acute liver failure and acute on chronic liver failure cases compared to chronic liver disease. FFP is not effective in correcting mild to moderate coagulation defects in liver diseases. Large volumes are required to cause significant INR improvement. Considering the risks associated with FFP transfusion, decision of transfusion should be carefully weighed. Future prospective randomized control trails are required for understanding the risk benefit ratio better and formulating plasma transfusion guidelines in liver diseases.

Entities:  

Keywords:  ALF; CLD; FFP; INR

Year:  2018        PMID: 30369747      PMCID: PMC6186240          DOI: 10.1007/s12288-018-0934-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  11 in total

1.  Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results.

Authors:  Lorne L Holland; Jay P Brooks
Journal:  Am J Clin Pathol       Date:  2006-07       Impact factor: 2.493

Review 2.  Blood component support in acquired coagulopathic conditions: is there a method to the madness?

Authors:  Trailokya Nath Pandit; Ravindra Sarode
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

3.  Management of coagulopathy in liver disease.

Authors:  Stephen H Caldwell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

4.  Hemostasis and thrombosis in patients with liver disease: the ups and downs.

Authors:  Ton Lisman; Stephen H Caldwell; Andrew K Burroughs; Patrick G Northup; Marco Senzolo; R Todd Stravitz; Armando Tripodi; James F Trotter; Dominique-Charles Valla; Robert J Porte
Journal:  J Hepatol       Date:  2010-05-12       Impact factor: 25.083

5.  An audit of fresh frozen plasma usage and effect of fresh frozen plasma on the pre-transfusion international normalized ratio.

Authors:  S A Shinagare; N N Angarkar; S R Desai; M R Naniwadekar
Journal:  Asian J Transfus Sci       Date:  2010-07

Review 6.  Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials.

Authors:  S J Stanworth; S J Brunskill; C J Hyde; D B L McClelland; M F Murphy
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

Review 7.  The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy.

Authors:  Simon J Stanworth
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

8.  Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study.

Authors:  Wael I Youssef; Fernando Salazar; Srinivasan Dasarathy; Timothy Beddow; Kevin Daniel Mullen
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

9.  Management of coagulopathy in patients with decompensated liver cirrhosis.

Authors:  Pooja D Amarapurkar; Deepak N Amarapurkar
Journal:  Int J Hepatol       Date:  2011-11-17

10.  The international normalized ratio does not reflect bleeding risk in esophageal variceal hemorrhage.

Authors:  Tammy T Hshieh; Aung Kaung; Syed Hussain; Michael P Curry; Vinay Sundaram
Journal:  Saudi J Gastroenterol       Date:  2015 Jul-Aug       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.